Quanterix maintains 2026 guidance despite steep organic declines, boosts Alzheimer’s diagnostics

 

Quanterix Q1 2026: EPS -$0.37, revenue $36.4M, maintains 2026 guidance despite steep organic declines, boosts Alzheimer’s diagnostics

• Q1 revenue was $36.4 million, +20% YoY but organic revenue declined 21%.
• Non-GAAP EPS for Q1 2026 was -$0.37, improving 30% YoY.
• Simoa revenue fell 21% organically and spatial revenue declined 26% amid tough end markets.
• Pharma revenue dropped 33% and academic revenue fell ~16% on a pro forma basis.
• Non-GAAP gross margin held at 50.9%, supported by realized Akoya cost synergies.
• Full-year 2026 revenue guidance of $169–$174 million and margin outlook were maintained.
• Management expects Q2 roughly in line with Q1 and a stronger, initiative-driven second half.
• Quanterix targets cash flow breakeven by Q4 2026, ending 2026 with about $100 million cash.
• Company is increasing investment in LucentAD Complete, expecting FDA clearance in 2H 2026.
• Upgraded HD-X platform is being prepared for IVD filing in 2027 to support diagnostics.
• Key risks are instrument softness, academic funding pressure, and execution on back-half-weighted guide.
• Main concern: Executing commercial initiatives to deliver a heavily second-half-weighted 2026 revenue plan in weak markets.
• Mixed quarter, driven by resilient margins and diagnostics progress offset by significant organic revenue pressure.

https://finviz.com/quote?t=QTRX&p=d